Medpace Inc.
http://www.medpace.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medpace Inc.
Hidden Dragon? Investors Return To New China Biotech Reality
Several Chinese biotech developments during the Lunar New Year break have put investors on high alert, namely the continued share price slide of Chinese biotech bellwether WuXi Apptec, Lianbio ceasing operations and I-Mab divesting its China business to become a fully US-focused company.
Asia Deal Watch: US Biotech LIB Partners In Greater China With Hasten On PCSK9 Therapy
Plus deals involving Astellas/Menarini, Maruho/Fortress Biotech, Zenas/Bristol Myers Squibb, Huadong Medicine/MC2 and more.
LIB Therapeutics Has An Unorthodox Funding Method And Big Plans
Armed with highly satisfactory Phase III cholesterol-lowering data, the private group is heading to market alone – though it is open to offers.
War on C Difficile Is Being Fought On Multiple Fronts
Pivotal trials are underway for two microbiota restoration therapies, a narrow-spectrum antibiotic and a vaccine; funding from non-profits and new owners have revived stalled projects at Summit, Deinove and MGB Biopharma.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Medical Devices
- Pharmaceuticals
- Services
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice